Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 4/20 | 1.00 |
| ▸ | EPAS1 | Q99814 | 4/20 | 1.00 |
| ▸ | NPC1 | O15118 | 5/20 | 0.68 |
| ▸ | RAB9A | P51151 | 4/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.68 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | MDH1 | P40925 | 1/20 | 0.64 |
| ▸ | MDH2 | P40926 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.60 |
| ▸ | MITF | O75030 | 1/20 | 0.60 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.60 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.60 |
| ▸ | RELA | Q04206 | 1/20 | 0.60 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.60 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.60 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30460318 | 1.00 | HIF1A (1.00) | HIF1AEPAS1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2953300 | 0.91 | HIF1A (0.83) | HIF1AEPAS1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL31303632 | 0.90 | HIF1A (0.81) | HIF1AEPAS1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2957387 | 0.90 | HIF1A (0.81) | HIF1AEPAS1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4296995 | 0.89 | HIF1A (0.80) | HIF1AEPAS1NPC1SMN1; SMN2MAPT | |
| SCHEMBL4298313 | 0.89 | HIF1A (0.80) | HIF1AEPAS1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL12171836 | 0.88 | HIF1A (0.78) | HIF1AEPAS1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2959279 | 0.87 | HIF1A (0.82) | HIF1AEPAS1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2950780 | 0.86 | HIF1A (0.77) | HIF1AEPAS1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2956553 | 0.86 | HIF1A (0.93) | HIF1AEPAS1NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140044684-A1 | Methods And Compositions For Regulating Gene Expression | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2014-02-13 | — | — | US | claimed |
| US-20090304641-A1 | Methods and Compositions for Regulating Gene Expression | CHILDREN'S HOSPITAL BOSTON (US) | 2009-12-10 | — | — | US | claimed |
| EP-2062578-A1 | Novel use of chemical compounds for the treatment of AIDS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2009-05-27 | — | — | EP | claimed |
| WO-2009063412-A1 | USE OF CHEMICAL COMPOUNDS FOR THE TREATMENT OF AIDS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2009-05-22 | — | — | WO | claimed |
| US-7247741-B2 | Acetylamino benzoic acid compounds and their use for nonsense suppression and the treatment of disease | PTC THERAPEUTICS, INC. (US) | 2007-07-24 | — | — | US | claimed |
| WO-2007047706-A2 | METHODS AND COMPOSITIONS FOR REGULATING GENE EXPRESSION | CHILDREN'S HOSPITAL (US) | 2007-04-26 | — | — | WO | claimed |
| US-20060167263-A1 | Acetylamino benzoic acid compounds and their use for nonsense suppression and the treatment of disease | PTC THERAPEUTICS, INC. | 2006-07-27 | — | — | US | claimed |
| EP-1525185-A1 | ACETYLAMINO BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC Therapeutics, Inc. (US) | 2005-04-27 | — | — | EP | claimed |
| WO-2004009533-A1 | ACETYLAMINO BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC THERAPEUTICS, INC. (US) | 2004-01-29 | — | — | WO | claimed |
| US-11517630-B2 | Methods and compositions for regulating gene expression | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2022-12-06 | — | — | US | disclosed |
| US-11352624-B2 | Reducing nonsense-mediated MRNA decay | COLD SPRING HARBOR LABORATORY (US) | 2022-06-07 | — | — | US | disclosed |
| US-20200283762-A1 | REDUCING NONSENSE-MEDIATED MRNA DECAY | COLD SPRING HARBOR LABORATORY (US) | 2020-09-10 | — | — | US | disclosed |
| EP-3690048-A1 | REDUCING NONSENSE-MEDIATED MRNA DECAY | COLD SPRING HARBOR LABORATORY (US) | 2020-08-05 | — | — | EP | disclosed |
| US-10647983-B2 | Reducing nonsense-mediated mRNA decay | COLD SPRING HARBOR LABORATORY (US) | 2020-05-12 | — | — | US | disclosed |
| US-7247741-B2 | Acetylamino benzoic acid compounds and their use for nonsense suppression and the treatment of disease | PTC THERAPEUTICS, INC. (US) | 2007-07-24 | — | — | US | disclosed |
| US-7247741-B2 | Acetylamino benzoic acid compounds and their use for nonsense suppression and the treatment of disease | PTC THERAPEUTICS, INC. (US) | 2007-07-24 | — | — | US | disclosed |
| WO-2007047706-A2 | METHODS AND COMPOSITIONS FOR REGULATING GENE EXPRESSION | CHILDREN'S HOSPITAL (US) | 2007-04-26 | — | — | WO | disclosed |
| US-20060167263-A1 | Acetylamino benzoic acid compounds and their use for nonsense suppression and the treatment of disease | PTC THERAPEUTICS, INC. | 2006-07-27 | — | — | US | disclosed |
| EP-1525185-A1 | ACETYLAMINO BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC Therapeutics, Inc. (US) | 2005-04-27 | — | — | EP | disclosed |
| WO-2004009533-A1 | ACETYLAMINO BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC THERAPEUTICS, INC. (US) | 2004-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167263-A1 | Acetylamino benzoic acid compounds and their use for nonsense suppression and the treatment of disease | UPF1, NAT10, PABPC1 | HIF1A 2314/4885EPAS1 1363/4885NPC1 1202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.